These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 17910234)

  • 1. Phase 0 trials speed early drug development.
    McBride D
    ONS Connect; 2007 Sep; 22(9):21. PubMed ID: 17910234
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biological markers: utilization in drug development and approval].
    Gueyffier F; Dib M; Boissel JP
    Therapie; 2001; 56(4):355-61. PubMed ID: 11677852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug development research: the process.
    Sataloff RT
    Ear Nose Throat J; 2008 Aug; 87(8):420-2. PubMed ID: 18712686
    [No Abstract]   [Full Text] [Related]  

  • 4. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can pharmacogenomics make a difference in drug development?
    Ledley FD
    Nat Biotechnol; 1999 Aug; 17(8):731. PubMed ID: 10429218
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug markers questioned.
    Ledford H
    Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good clinical practice in clinical drug trials--what you need to know.
    Soyebi K; Abosede ; Coker HA; Osuntoki ; Oyibos W; Keri H; Ogunsola S
    Nig Q J Hosp Med; 2008; 18(2):104-12. PubMed ID: 19068563
    [No Abstract]   [Full Text] [Related]  

  • 10. Surrogate markers in clinical studies: problems solved or created?
    Manns B; Owen WF; Winkelmayer WC; Devereaux PJ; Tonelli M
    Am J Kidney Dis; 2006 Jul; 48(1):159-66. PubMed ID: 16797400
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Biomarkers Forum: harnessing the potential of biomarkers from translational research throughout clinical trials.
    Shaw M
    Expert Rev Mol Diagn; 2007 Nov; 7(6):759-60. PubMed ID: 18020905
    [No Abstract]   [Full Text] [Related]  

  • 12. Good clinical practice--a practical experience.
    Ogunsola FT
    Nig Q J Hosp Med; 2008; 18(2):123-4. PubMed ID: 19068567
    [No Abstract]   [Full Text] [Related]  

  • 13. Complement inhibitors finally find orphan niches.
    Ratner M
    Nat Biotechnol; 2006 Apr; 24(4):371-2. PubMed ID: 16601706
    [No Abstract]   [Full Text] [Related]  

  • 14. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
    Shah RR
    Pharmacol Ther; 2008 Aug; 119(2):215-21. PubMed ID: 18455801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation.
    Barrett JS; Shi J; Xie HT; Huang XH; Fossler MJ; Sun RY
    J Clin Pharmacol; 2008 Jul; 48(7):787-92. PubMed ID: 18490494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronicles in drug discovery.
    Cole P; Vasiliou S
    Drug News Perspect; 2010 Mar; 23(2):138-42. PubMed ID: 20369079
    [No Abstract]   [Full Text] [Related]  

  • 20. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
    Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
    J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.